We next assessed two additional blood‐based markers, pre‐surgery circulating tumour DNA‐based KRAS mutation detection (ctKRAS) and CA19‐9, as well as primary tumour volume as measured from pre‐surgery imaging. The gene discussed is KRAS; the disease is neoplasm.